The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
- 29 February 2004
- journal article
- research article
- Published by Elsevier BV in Urologic Oncology
- Vol. 22 (1), 16-19
- https://doi.org/10.1016/s1078-1439(03)00098-x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- PROSPECTIVE EVALUATION OF GENETIC ABNORMALITIES AND TELOMERASE EXPRESSION IN EXFOLIATED URINARY CELLS FOR BLADDER CANCER DETECTIONJournal of Urology, 2002
- Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysisInternational Journal of Cancer, 2001
- CURRENT BLADDER TUMOR TESTS: DOES THEIR PROJECTED UTILITY FULFILL CLINICAL NECESSITY?Journal of Urology, 2001
- Karyotypic characterization of urinary bladder transitional cell carcinomasGenes, Chromosomes and Cancer, 2000
- A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, 2000
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000
- Urinary markers of malignancyClinica Chimica Acta; International Journal of Clinical Chemistry, 2000
- High-resolution cytometry of FISH dots in interphase cell nucleiCytometry, 1999
- RAPID PROTECTION OF BLADDER CANCER: A COMPARATIVE STUDY OF POINT OF CARE TESTSJournal of Urology, 1997
- Interphase cytogenetics using fluorescence in situ hybridization: an overview of its application to diffuse and solid tissueBrazilian Journal of Genetics, 1997